Literature DB >> 7852052

Suppression of experimental autoimmune encephalomyelitis by cannabinoids.

I Wirguin1, R Mechoulam, A Breuer, E Schezen, J Weidenfeld, T Brenner.   

Abstract

The effect of delta 8-THC on experimental autoimmune encephalomyelitis (EAE) was examined. delta 8-THC is an analogue of delta 9-THC, the psychoactive component of marijuana. It is more stable and less psychotropic than delta 9-THC and like the latter it binds to the brain cannabinoid receptor. Two strains of rats were inoculated for EAE, and delta 8-THC (40 mg/kg) was administered for up to 21 days. delta 8-THC significantly reduced the incidence and severity of neurological deficit in both rat strains. The beneficial influence of delta 8-THC only occurred on oral administration and not with parenteral injection. Serum corticosterone levels were twofold elevated in rats with EAE chronically treated with delta 8-THC. These results suggest that suppression of EAE by cannabinoids may be related to their effect on corticosterone secretion.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7852052     DOI: 10.1016/0162-3109(94)90056-6

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


  24 in total

Review 1.  G protein-coupled receptors as therapeutic targets for multiple sclerosis.

Authors:  Changsheng Du; Xin Xie
Journal:  Cell Res       Date:  2012-06-05       Impact factor: 25.617

Review 2.  The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.

Authors:  Roger G Pertwee
Journal:  AAPS J       Date:  2005-10-24       Impact factor: 4.009

3.  Multiple sclerosis may disrupt endocannabinoid brain protection mechanism.

Authors:  Esther Shohami; Raphael Mechoulam
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-10       Impact factor: 11.205

4.  Cannabis and endocannabinoid modulators: Therapeutic promises and challenges.

Authors:  Igor Grant; B Rael Cahn
Journal:  Clin Neurosci Res       Date:  2005

Review 5.  [Therapeutic use of cannabinoids in neurology].

Authors:  P Schwenkreis; M Tegenthoff
Journal:  Schmerz       Date:  2003-10       Impact factor: 1.107

Review 6.  Biosynthesis of endocannabinoids and their modes of action in neurodegenerative diseases.

Authors:  Mario van der Stelt; Henrik H Hansen; Wouter B Veldhuis; Peter R Bär; Klaas Nicolay; Gerrit A Veldink; Johannes F G Vliegenthart; Harald S Hansen
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

Review 7.  Cannabinoids and multiple sclerosis.

Authors:  Roger G Pertwee
Journal:  Mol Neurobiol       Date:  2007-06-26       Impact factor: 5.590

Review 8.  Cannabinoids in multiple sclerosis: do they have a therapeutic role?

Authors:  Joep Killestein; Bernard M J Uitdehaag; Chris H Polman
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 9.  Direct suppression of autoreactive lymphocytes in the central nervous system via the CB2 receptor.

Authors:  B N Dittel
Journal:  Br J Pharmacol       Date:  2007-10-08       Impact factor: 8.739

10.  Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55,212.

Authors:  J Ludovic Croxford; Stephen D Miller
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.